Real-time molecular vision

Truth in Every Layer: Real-Time AI for Surgery & Diagnostics

Reveal Life Science

Bringing Molecular Intelligence Into Clinical Practice

Reveal Life Science is a clinically validated technology platform advancing toward clinical deployment across pathology, surgery, and biofluid-based monitoring.

Built on over a decade of research and validated across more than 500 patients and 20,000 tissue samples, Reveal is transitioning from development to real-world clinical applications.

Clinical products are developed and advanced through dedicated programs and affiliates, including Reveal Surgical.

Contact us

Product Lines

Clarion™ is a clinical application enabling real-time molecular assessment of tissue during sampling, improving diagnostic confidence and reducing repeat procedures.

Learn more
Reveal Sage™ is a research program exploring biofluid spectroscopy to bring lab-grade diagnostics to saliva, urine, and blood testing.

Learn more
Reveal Sentry™ is an investigational intraoperative system providing real-time molecular insight during cancer surgery to support more precise surgical decisions.

Learn more
Reveal Atlas™ combines molecular analytics, AI, and cloud infrastructure to generate real-time insights from spectral data as a research dataset for model development—not a clinical product.

Learn more

A 3D projection ruler with measurements on four triangular sides, each marked with inches, used for geometric or technical drafting.

Digital abstract art with colorful geometric shapes, connected lines, and gradient shading.

Platform Overview

Reveal Life Science develops a molecular sensing and AI platform designed to support regulated clinical applications and future diagnostic systems.

The platform is deployed through a staged strategy:

A 3D visualization of a black area filled with white and gray dots at the bottom, with black space above.

Pathology

initial clinical entry point through tissue assessment

SURGERY

intraoperative molecular characterization

Biofluids

longitudinal biological monitoring programs

From Validation to Deployment

Rather than operating solely as an R&D engine, Reveal is advancing a structured transition from validation to clinical deployment and scalable applications.

CLARION™ — PATHOLOGY APPLICATION

Advancing Toward Clinical Deployment

Clarion™ is the first clinical application of the Reveal platform, designed to assess tissue adequacy using molecular sensing at the point of sampling.

Clinical Context

In biopsy and surgical workflows, clinicians often lack immediate confirmation that collected tissue is adequate for diagnosis.

This can lead to:

repeat procedures
delays in diagnosis
increased patient burden

Approach

Clarion™ uses Raman spectroscopy and AI to analyze the molecular composition of tissue samples in near real time.

The system is designed to:

support assessment of tissue adequacy
improve confidence during sampling
integrate into existing clinical workflows

Development and Regulatory Status

Clarion™ is currently in advanced development and preparing for initial clinical deployment.

validated on extensive clinical datasets
undergoing system finalization and verification
preparing for submission under a Health Canada Class II regulatory pathway

Early Access Program — Clarion™

Reveal is engaging a limited number of clinical partners to support the evaluation and refinement of Clarion™ ahead of regulatory submission.

Selected sites will participate in:

workflow integration and usability assessment
performance validation in real clinical settings
early access to platform capabilities

We are currently onboarding a small number of early access sites.

STRATEGIC ROLE

Clarion™ represents the initial clinical entry point for the Reveal platform.

It enables:

early clinical adoption
generation of real-world data
foundation for expansion into surgical and biofluid applications

Clarion™ is expected to represent the initial commercial pathway for the platform following regulatory clearance.

A scientist is using a dropper to transfer a liquid into a petri dish in a laboratory setting with a microscope in the background.

REVEAL SAGE™

Longitudinal Biological Monitoring

Reveal Sage™ is a structured research and validation program exploring the use of molecular sensing in biofluids such as blood, urine, and saliva.

Pilot Program — SAGE™

Reveal is initiating structured pilot programs with institutional and government partners to validate longitudinal biofluid monitoring.

Programs are designed to:

generate longitudinal biological datasets
validate molecular signal detection
support future clinical and public health applications

THE PROGRAM WILL ALLOW:

the detection molecular patterns over time
the generation longitudinal biological datasets
the development future diagnostic applications

SAGE™ product development is being accelerated through strategic pilot programs conducted in collaboration with institutional and government partners.

Typical pilot programs:

$3M–$10M scope
12–18 month duration
multi-cohort deployment

SAGE™ is not a commercial diagnostic product at this stage and is being developed as a structured validation and data-generation platform.

SENTRY™ SURGICAL PLATFORM

Molecular intelligence for clinical decision-making

Sentry™ is the core system powering Reveal's clinical platform, designed to transform molecular signals into actionable insight across multiple clinical applications.

Applications

Sentry™ Precision — Neurosurgery

Investigational intraoperative system being advanced to support tissue characterization during brain tumor surgery.
Advancing through a U.S. FDAPMA regulatory pathway.
Sentry™ Scanner — Breast Surgery

Investigational ex vivo system designed to support tissue assessment during surgical procedures.
Navisense™ — Interventional Guidance

Investigational system designed to support tissue targeting during minimally invasive procedures. FDA 510(k) pathway anticipated.

Built on a Shared Platform

All applications are built on the same core Sentry™ platform, enabling scalable deployment across clinical workflows and expansion into additional indications without redesigning the underlying system.

Real-Time Insight

Intraoperative decision-support technologies for tissue characterization

- Investigational intraoperative tissue characterization system for neurosurgery
- Intended to provide real-time molecular information to support surgical decision-making during brain tumor resection
- FDAPMA regulatory pathway
- Investigational ex vivo tissue assessment system for breast surgery
- Intended to support intraoperative evaluation of resected tissue margins during lumpectomy procedures
- Investigational endoscopic tissue guidance system
- Intended to support tissue targeting during minimally invasive endoscopic procedures
- 510(k) regulatory pathway anticipated

Why This Matters Now

validated clinical foundation
regulatory pathways defined
first application advancing toward deployment
strategic partners engaged

Clinical Collaboration — Neurosurgery Program

Reveal is working with leading clinical institutions to advance the Sentry™ neurosurgery application through focused studies and workflow integration.

Opportunities include:

participation in clinical evaluation programs
collaboration on study design and data generation
early engagement with the Sentry™ platform

Visit the website

REVEAL INSIGHT ATLAs™

Data Platform for Molecular Intelligence

Reveal Insight Atlas™ is a research and data platform supporting the development of molecular intelligence models.

By aggregating spectral data from clinical studies, Atlas™ enables:

continuous optimization of AI models
validation of molecular patterns
development of future clinical applications

Atlas™ is not a clinical product and is not used for real-time medical decision-making.

Unleashing the Power of Real‑Time Molecular Insights

Faster Than Ever

Detect critical changes in real time, from cancer cells to environmental anomalies, with results in seconds.
A Unique Data Source

Reveal A.I builds an unprecedented molecular database − rich in biomarkers, spectra, and physico‑chemical patterns − that drives smarter therapeutic decisions and innovations.
Cost‑Effective Precision

Diagnostics that aim to improve speed and accessibility, supporting broader access to high-impact testing.
Non‑Invasive & Multi‑Purpose

Analyze biofluids, environmental samples, and industrial liquids without invasive procedures or sample preparation.
Proactive Health Monitoring

Potential to support faster clinical monitoring across a range of health conditions.
Remote-Ready Technology

Deployable in remote or extreme environments, ensuring vital data collection and diagnostics anywhere.
AI-Powered Evolution

Our proprietary SaaS platform continuously integrates new capabilities and biomarkers via simple software updates, adapting to emerging needs.
Validated by Global Experts

Backed by over 9 years of research and 180+ peer-reviewed publications, trusted by hospitals, universities, and government institutions across three continents.
Multi-Domain Impact

From precision surgery to pandemic prevention, Reveal Explorer and Reveal SENTRY™ support smarter decisions in healthcare, animal health, food safety, and industrial monitoring.